Structure-Activity Relationships for CYP4B1 Bioactivation of 4-Ipomeanol Congeners: Direct Correlation between Cytotoxicity and Trapped Reactive Intermediates

被引:10
|
作者
Kowalski, John P. [1 ]
McDonald, Matthew G. [1 ]
Whittington, Dale [1 ]
Guttman, Miklos [1 ]
Scian, Michele [1 ]
Girhard, Marco [2 ]
Hanenberg, Helmut [3 ]
Wiek, Constanze [4 ]
Rettie, Allan E. [1 ]
机构
[1] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98105 USA
[2] Heinrich Heine Univ, Inst Biochem, D-40225 Dusseldorf, Germany
[3] Univ Duisburg Essen, Univ Childrens Hosp Essen, Dept Pediat 3, D-45122 Essen, Germany
[4] Heinrich Heine Univ, Dept Otorhinolaryngol & Head Neck Surg, D-40225 Dusseldorf, Germany
关键词
COVALENT BINDING; RABBIT CYP4B1; IN-VITRO; CYTOCHROME-P450; METABOLITES; CANCER; HEME; P450; CELL; IDENTIFICATION;
D O I
10.1021/acs.chemrestox.9b00330
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cytochrome P450 4B1 (CYP4B1) has been explored as a candidate enzyme in suicide gene systems for its ability to bioactivate the natural product 4-ipomeanol (IPO) to a reactive species that causes cytotoxicity. However, metabolic limitations of IPO necessitate discovery of new "pro-toxicant" substrates for CYP4B1. In the present study, we examined a series of synthetically facile N-alkyl-3-furancarbox-amides for cytotoxicity in HepG2 cells expressing CYP4B1. This compound series maintains the furan warhead of IPO while replacing its alcohol group with alkyl chains of varying length (C1-C8). Compounds with C3-C6 carbon chain lengths showed similar potency to IPO (LD50 approximate to 5 mu M). Short chain analogs (<3 carbons) and long chain analogs (>6 carbons) exhibited reduced toxicity, resulting in a parabolic relationship between alkyl chain length and cytotoxicity. A similar parabolic relationship was observed between alkyl chain length and reactive intermediate formation upon trapping of the putative enedial as a stable pyrrole adduct in incubations with purified recombinant rabbit CYP4B1 and common physiological nucleophiles. These parabolic relationships reflect the lower affinity of shorter chain compounds for CYP4B1 and increased omega-hydroxylation of the longer chain compounds by the enzyme. Furthermore, modest time-dependent inhibition of CYP4B1 by N-pentyl-3-furancarboxamide was completely abolished when trapping agents were added, demonstrating escape of reactive intermediates from the enzyme after bioactivation. An insulated CYP4B1 active site may explain the rarely observed direct correlation between adduct formation and cell toxicity reported here.
引用
收藏
页码:2488 / 2498
页数:11
相关论文
共 50 条
  • [1] Bioactivation of 4-Ipomeanol by CYP4B1: Adduct characterization and evidence for an enedial intermediate
    Baer, BR
    Rettie, AE
    Henne, KR
    CHEMICAL RESEARCH IN TOXICOLOGY, 2005, 18 (05) : 855 - 864
  • [2] Reactive intermediates of 4-ipomeanol formed by CYP4B1: Evidence for an ene-dial intermediate
    Baer, BR
    Henne, KR
    Rettie, AE
    DRUG METABOLISM REVIEWS, 2004, 36 : 224 - 224
  • [3] CYP4B1 ACTIVATES 4-IPOMEANOL IN RAT LUNG
    VERSCHOYLE, RD
    PHILPOT, RM
    WOLF, CR
    DINSDALE, D
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1993, 123 (02) : 193 - 198
  • [4] Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol
    Wiek, Constanze
    Schmidt, Eva M.
    Roellecke, Katharina
    Freund, Marcel
    Nakano, Mariko
    Kelly, Edward J.
    Kaisers, Wolfgang
    Yarov-Yarovoy, Vladimir
    Kramm, Christof M.
    Rettie, Allan E.
    Hanenberg, Helmut
    BIOCHEMICAL JOURNAL, 2015, 465 : 103 - 114
  • [5] Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter
    Hsu, H
    Rainov, NG
    Quinones, A
    Eling, DJ
    Sakamoto, KM
    Spear, MA
    ANTICANCER RESEARCH, 2003, 23 (3B) : 2723 - 2728
  • [6] 4-Ipomeanol (4-IM) toxicity through induction of cytochrome CYP4B1 under an EGR1 promoter
    Hsu, H
    Rainov, NG
    Sun, F
    Sakamoto, KM
    Spear, MA
    CANCER GENE THERAPY, 1999, 6 (06) : S23 - S23
  • [7] Synthesis and Evaluation of a 18F-Labeled 4-Ipomeanol as an Imaging Agent for CYP4B1 Gene Prodrug Activation Therapy
    Moon, Byung Seok
    Jang, Su Jin
    Kim, Sung Joo
    Lee, Tae Sup
    Chi, Dae Yoon
    Lee, Byung Chul
    Kang, Joo Hyun
    Kim, Sang Eun
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2013, 28 (08) : 588 - 597
  • [8] Re-engineering of human CYP4B1 for optimal catalytic processing of 4-ipomeanol and use as a suicide gene in adoptive cell therapy
    Wiek, C.
    Roellecke, K.
    Schmidt, E. M.
    Kramm, C. M.
    Rettie, A. E.
    Hanenberg, H.
    HUMAN GENE THERAPY, 2014, 25 (11) : A50 - A50
  • [9] Structure-activity relationships of CYP4A1
    Holmes, VE
    Qi, FM
    Laughton, CA
    Bell, DR
    Shaw, PN
    Barrett, DA
    TOXICOLOGY, 2002, 178 (01) : 43 - 44
  • [10] Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies
    Roellecke, K.
    Virts, E. L.
    Einholz, R.
    Edson, K. Z.
    Altvater, B.
    Rossig, C.
    von Laer, D.
    Scheckenbach, K.
    Wagenmann, M.
    Reinhardt, D.
    Kramm, C. M.
    Rettie, A. E.
    Wiek, C.
    Hanenberg, H.
    GENE THERAPY, 2016, 23 (07) : 615 - 626